<acronym id="k92hb"><label id="k92hb"></label></acronym>


      Hunan Zhongnan Pharmaceutical Co., Ltd., formerly known as Zhongnan pharmaceutical factory, was founded in 1968. It is located in longxutang, Shuangqing District, Shaoyang City, Hunan Province. It covers an area of 200000 square meters and has a total asset of 135 million yuan. It has the right to import and export its own products and technologies. It is one of the 38 key pharmaceutical enterprises in the original national pharmaceutical industry and one of the National Chemical API production base.

      In July 2003, the enterprise was restructured into Hunan Zhongnan Pharmaceutical Co., Ltd., which is now a joint-stock enterprise. After the restructuring, the company has reformed the plant, equipment and facilities in strict accordance with GMP requirements, and successfully passed the first GMP certification in July 2004. It is the first enterprise in Shaoyang City and the earlier one in Hunan Pharmaceutical industry. It passed the re certification in 2009, and passed the new GMP certification in 2014 and 2017. The company now has more than ten production lines for tablets, capsules, granules, creams, hormone preparations and APIs, equipped with advanced detection instruments such as high-performance liquid phase, gas phase, infrared, UV, etc., organized production in strict accordance with the new GMP standard of the state, and constantly improved the quality management system, including aspirin, pentafluridol tablets, olamet tablets, compound proglumide tablets, etc More than 10 products have won the titles of provincial and ministerial excellent products. The preparation workshop has an annual production capacity of 1 billion tablets. Now it has developed into a comprehensive enterprise integrating R & D, production and sales of APIs, preparations and pharmaceutical intermediates.

      At present, the company has 34 kinds of preparation, including compound proglumide tablets, aspirin tablets, pentafluridol tablets, and auramide tablets, among which 14 kinds and specifications of drugs are selected into the national basic drug catalog; raw materials include aspirin, pentafluridol, auramide; pharmaceutical intermediates include ACA, ACA hydrochloride, etc. The products are mainly used in the treatment of mental illness, liver disease, stomach disease, cold, pain relief and so on. They are sold all over the country and well received by users.

      No pains, no gains. On the one hand, the company has established a modern enterprise system, strict internal management and solid foundation for enterprise development; on the other hand, it has set up a strong scientific research team to adhere to scientific and technological innovation. The company has been listed in 60 listed key cultivation objects and the first 19 listed supporting enterprises in Hunan Province, striving for the successful listing of small and medium-sized boards during the 13th Five Year Plan period.